25 October 2016

Promotion to the Partnership of James Pitchford, James Wilding, Monika Rai and Stephen Garner

We are delighted to announce the promotion to the Partnership of James Pitchford, James Wilding, Monika Rai and Stephen Garner.

James PitchfordDr James Pitchford specialises in patent work in the physics, electronics, engineering and materials science sectors. James is experienced in opposition and appeal proceedings before the European Patent Office. James obtained an MA honours degree in natural sciences (physics and materials science) and a PhD in materials science, both from the University of Cambridge.
James Wilding

Dr James Wilding practices in the areas of biochemistry, biotechnology and immunology, with a particular focus on therapeutic antibodies, cell-based therapies, vaccines and gene editing. He has extensive experience in handling oppositions and appeals at the European Patent Office and is considered to be an expert within the field of SPCs.

monika raj 2016Monika Rai has particular expertise in the areas of proteins and peptides, nucleic acid therapies, probiotics and diagnostics. She represents clients in both prosecution and opposition proceedings at the European Patent Office, and is also heavily involved in conducting and coordinating major IP due diligence projects, including those involving freedom to operate reviews and licensing agreements. She is qualified as a Solicitor (England & Wales) and holds a Higher Courts Litigation Certificate providing enhanced rights to conduct IP litigation in the UK courts.
Stephen GarnerDr Stephen Garner has a practice that extends from chemistry, pharmaceuticals and nutritionals, through to protein and antibody therapies. He works with a diverse range of clients, from universities and SMEs to multinational corporations, and is highly regarded for his expertise in tailoring to their business needs all areas of patenting from drafting and prosecution, to oppositions, SPCs and life cycle management. He manages large patent portfolios for international pharmaceutical companies and has significant experience in obtaining and defending European patents for blockbuster drugs.